ORCID Profile
0000-0002-9955-4753
Current Organisations
Seoul National University
,
Korea Basic Science Institute
,
Université de Paris
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Related Links
Publications
Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
Publisher: Elsevier BV
Date: 03-2023
Technical note: Optimizing the utility of combined GPR, OSL, and Lidar (GOaL) to extract paleoenvironmental records and decipher shoreline evolution
Publisher: Copernicus GmbH
Date: 28-02-2221
Abstract: Abstract. Records of past sea levels, storms, and their impacts on coastlines are crucial for forecasting and managing future changes resulting from anthropogenic global warming. Coastal barriers that have prograded over the Holocene preserve within their accreting sands a history of storm erosion and changes in sea level. High-resolution geophysics, geochronology, and remote sensing techniques offer an optimal way to extract these records and decipher shoreline evolution. These methods include light detection and ranging (lidar) to image the lateral extent of relict shoreline dune morphology in 3-D, ground-penetrating radar (GPR) to record paleo-dune, beach, and nearshore stratigraphy, and optically stimulated luminescence (OSL) to date the deposition of sand grains along these shorelines. Utilization of these technological advances has recently become more prevalent in coastal research. The resolution and sensitivity of these methods offer unique insights on coastal environments and their relationship to past climate change. However, discrepancies in the analysis and presentation of the data can result in erroneous interpretations. When utilized correctly on prograded barriers these methods (independently or in various combinations) have produced storm records, constructed sea-level curves, quantified sediment budgets, and deciphered coastal evolution. Therefore, combining the application of GPR, OSL, and Lidar (GOaL) on one prograded barrier has the potential to generate three detailed records of (1) storms, (2) sea level, and (3) sediment supply for that coastline. Obtaining all three for one barrier (a GOaL hat-trick) can provide valuable insights into how these factors influenced past and future barrier evolution. Here we argue that systematically achieving GOaL hat-tricks on some of the 300+ prograded barriers worldwide would allow us to disentangle local patterns of sediment supply from the regional effects of storms or global changes in sea level, providing for a direct comparison to climate proxy records. Fully realizing this aim requires standardization of methods to optimize results. The impetus for this initiative is to establish a framework for consistent data collection and analysis that maximizes the potential of GOaL to contribute to climate change research that can assist coastal communities in mitigating future impacts of global warming.
Technical note: Optimizing the utility of combined GPR, OSL, and LiDAR (GOaL) to extract paleoenvironmental records and decipher shoreline evolution
Publisher: Copernicus GmbH
Date: 30-01-2018
DOI: 10.5194/CP-2018-4
Abstract: Abstract. Records of past sea levels, storms, and their impacts on coastline are crucial in forecasting future changes resulting from anthropogenic global warming. Coastal barriers that have prograded over the Holocene preserve within their accreting sands history of storm erosion and changes in sea level. High-resolution geophysics, geochronology, and remote sensing techniques offer an optimal way to extract these records and decipher shoreline evolution: Light Detection and Ranging (LiDAR) images the lateral extent of relict shoreline dune morphology Ground Penetrating Radar (GPR) data records paleo-dune, beach and nearshore stratigraphy Optically Stimulated Luminescence (OSL) dates when sand grains were deposited that form these shorelines. Utilization of these technological advances has recently become more prevalent in coastal research. The resolution and sensitivity of these methods offer unique insights on coastal environments and their relationship to past climate change. However, discrepancies in analysis and presentation of the data can result in erroneous interpretations. When utilized correctly on prograded barriers these methods (independently or in various combinations) have produced storm records, constructed sea-level curves, quantified sediment budgets, and deciphered coastal evolution. Therefore, combining the application of GPR, OSL, and LiDAR (GOaL) on one prograded barrier has the potential to generate detailed records of storms, sea level, and sediment supply for that coastline. Obtaining this GOaL hat-trick can provide valuable insights into how these three factors influenced past and future barrier evolution. Here we argue that systematically achieving GOaL hat-tricks on some of the 300+ prograded barriers worldwide would allow us to disentangle local patterns of sediment supply from regional effects of storms or global changes in sea level, allowing direct comparison to climate proxy records. To fully realize this aim requires standardization of methods to optimize results. The impetus for this initiative is to establish a framework for consistent data analysis that maximizes the potential of GOaL to contribute to climate change research and assist coastal communities in mitigating future impacts of global warming.
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy
Publisher: Springer Science and Business Media LLC
Date: 27-01-2023
DOI: 10.1186/S12885-022-10489-4
Abstract: PRECONNECT was an international, phase IIIb trial evaluating the safety and efficacy of trifluridine/tipiracil (FTD/TPI) for metastatic colorectal cancer (mCRC). Patients with mCRC received FTD/TPI 35 mg/m 2 twice-daily on days 1–5 and 8–12 of each 28-day cycle for third- or later-line treatment. Primary endpoint: safety and time to deterioration of Eastern Cooperative Oncology Group performance status [ECOG PS] to ≥2). Secondary endpoints included progression-free survival (PFS). Potential prognostic factors for PFS were explored. Of 914 patients, 69% completed 0–3, 24% completed 4–7, and 7% completed ≥8 cycles of FTD/TPI. Drug-related grade ≥ 3 adverse events included neutropenia (38.1%), anaemia (7.2%) and asthenia (3.4%). Median [95% CI] time to ECOG PS deterioration was 8.7 [8.1-not calculable] months and increased with duration of treatment (DoT). Median PFS was 2.8 [2.7–3.0] months and increased with duration of treatment DoT. Prognostic factors associated with longer PFS included time since diagnosis of first metastasis, number of metastatic sites, baseline ECOG PS, presence/absence of liver metastasis or previous regorafenib treatment, and laboratory variables. No new safety concerns for FTD/TPI were identified and PFS increased with DoT. These data provide confidence for the use of FTD/TPI, including the use of multiple cycles, in routine practice. EudraCT Number: 2016-002311-18 registered 19/09/2016. t2/show/NCT03306394 registered 11/10/2017.
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
Publisher: Future Medicine Ltd
Date: 02-2019
Abstract: Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in early phase studies in advanced/metastatic gastric/gastroesophageal junction cancer, including as first-line maintenance therapy. Here, we describe the design of JAVELIN Gastric 100 (NCT02625610), an open-label, Phase III trial. A total of 499 patients with locally advanced/metastatic HER2- gastric/gastroesophageal junction cancer adenocarcinoma, who had achieved at least stable disease following 12 weeks of first-line oxaliplatin/fluoropyrimidine chemotherapy, have been randomized 1:1 to receive avelumab maintenance therapy or continue chemotherapy. The primary objective is to demonstrate superior overall survival in all randomized patients or in the PD-L1+ population. Secondary objectives are to demonstrate superiority for progression-free survival and objective response rate, compare quality of life measures, and determine safety.
Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies
Publisher: Future Medicine Ltd
Date: 09-2023
Abstract: Background: QLQ-C30 Global Health Status (GHS) and Eastern Cooperative Oncology Group performance status (ECOG PS) data from PRECONNECT and TALLISUR studies were pooled. Materials & methods: Association between changes in ECOG PS and QLQ-C30 GHS in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) was evaluated using Cox regression analysis. Results: 1100 patients were included. There was no clinically relevant change from baseline in QLQ-C30 GHS score through cycle 7. 63.0% of patients maintained/improved ECOG PS. The presence of liver metastasis increased the risk of QLQ-C30 GHS score/ECOG PS deterioration. The association between time to ECOG PS deterioration and change in QLQ-C30 GHS score over time was significant (HR 1.71 [95% CI: 1.4, 2.2]). Conclusion: ECOG PS and QLQ-C30 GHS scores were maintained during FTD/TPI treatment, and these measures were associated. Factors that increased the risk of deterioration included the presence of liver/lung metastasis, younger age and shorter time since first metastasis. Clinical Trial Registration: PRECONNECT (EudraCT Number: 2016-002311-18 ) and TALLISUR (EudraCT-Number: 2017-000292-83 ).
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Publisher: American Society of Clinical Oncology (ASCO)
Date: 20-03-2021
DOI: 10.1200/JCO.20.00892
Abstract: The role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti–programmed death ligand-1 [PD-L1]) maintenance after first-line induction chemotherapy for GC/GEJC. JAVELIN Gastric 100 was a global, open-label, phase III trial. Eligible patients had untreated, unresectable, human epidermal growth factor receptor 2–negative, locally advanced or metastatic GC or GEJC. Patients without progressive disease after 12 weeks of first-line chemotherapy with oxaliplatin plus a fluoropyrimidine were randomly assigned 1:1 to avelumab 10 mg/kg every 2 weeks or continued chemotherapy, stratified by region (Asia v non-Asia). The primary end point was overall survival (OS) after induction chemotherapy in all randomly assigned patients or the PD-L1–positive randomly assigned population (≥ 1% of tumor cells 73-10 assay). A total of 805 patients received induction 499 were randomly assigned to avelumab (n = 249) or continued chemotherapy (n = 250). Median OS was 10.4 months (95% CI, 9.1 to 12.0 months) versus 10.9 months (95% CI, 9.6 to 12.4 months) and 24-month OS rate was 22.1% versus 15.5% with avelumab versus chemotherapy, respectively (hazard ratio [HR], 0.91 95% CI, 0.74 to 1.11 P = .1779). In the PD-L1–positive population (n = 54), the HR for OS was 1.13 (95% CI, 0.57 to 2.23 P = .6352). In an exploratory analysis of the PD-L1–positive population, defined as combined positive score ≥ 1 (22C3 assay n = 137), median OS was 14.9 months (95% CI, 8.7 to 17.3 months) with avelumab versus 11.6 months (95% CI, 8.4 to 12.6 months) with chemotherapy (unstratified HR, 0.72 95% CI, 0.49 to 1.05). With avelumab and chemotherapy, treatment-related adverse events (TRAEs) occurred in 149 (61.3%) and 184 (77.3%) patients, including grade ≥ 3 TRAEs in 31 (12.8%) and 78 (32.8%) patients, respectively. JAVELIN Gastric 100 did not demonstrate superior OS with avelumab maintenance versus continued chemotherapy in patients with advanced GC or GEJC overall or in a prespecified PD-L1–positive population.
Related Organisations
Related Funding Activities
No related grants have been discovered for julien taieb.